Financial Review: Astria Therapeutics (NASDAQ:ATXS) versus Swedish Orphan Biovitrum (OTCMKTS:BIOVF)

Astria Therapeutics (NASDAQ:ATXS) and Swedish Orphan Biovitrum (OTCMKTS:BIOVF) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, profitability and institutional ownership.

Earnings and Valuation

This table compares Astria Therapeutics and Swedish Orphan Biovitrum”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Astria Therapeutics	N/A	N/A	-$94.26 million	($2.14)	-5.84
Swedish Orphan Biovitrum	$2.46 billion	5.35	$367.52 million	($0.07)	-528.57

Swedish Orphan Biovitrum has higher revenue and earnings than Astria Therapeutics. Swedish Orphan Biovitrum is trading at a lower price-to-earnings ratio than Astria Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Astria Therapeutics and Swedish Orphan Biovitrum’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Astria Therapeutics	N/A	-68.81%	-41.12%
Swedish Orphan Biovitrum	-0.97%	13.66%	7.50%

Risk & Volatility

Astria Therapeutics has a beta of 0.01, indicating that its share price is 99% less volatile than the S&P 500. Comparatively, Swedish Orphan Biovitrum has a beta of 0.37, indicating that its share price is 63% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and price targets for Astria Therapeutics and Swedish Orphan Biovitrum, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Astria Therapeutics	1	8	2	0	2.09
Swedish Orphan Biovitrum	0	0	1	0	3.00

Astria Therapeutics presently has a consensus price target of $24.50, suggesting a potential upside of 96.00%. Given Astria Therapeutics’ higher possible upside, equities research analysts plainly believe Astria Therapeutics is more favorable than Swedish Orphan Biovitrum.

Insider and Institutional Ownership

99.0% of Astria Therapeutics shares are owned by institutional investors. 4.5% of Astria Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Swedish Orphan Biovitrum beats Astria Therapeutics on 7 of the 13 factors compared between the two stocks.

About Astria Therapeutics

Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is headquartered in Boston, Massachusetts.

About Swedish Orphan Biovitrum

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); VONJO for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis; Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still’s disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. The company also provides other products, such as Akynzeo, Tegsedi, Jyseleca, Kepivance, Aloxi, and Waylivra. In addition, it develops drug substance for ReFacto AF/Xyntha for Pfizer; BIVV001 for haemophilia A; and Nirsevimab for respiratory syncytial virus. The company has a strategic collaboration with Sanofi, Apellis Pharmaceuticals Inc., ADC Therapeutics SA, and Cartesian Therapeutics, Inc. Swedish Orphan Biovitrum AB (publ) was incorporated in 1939 and is headquartered in Solna, Sweden.